Conjunctival pigmented masses
Conditions
Interventions
conjunctival nevus:Follow-up (no malignancy)/local use of immunomodulators (partial malignancy)
primary acquired melanosis:Follow-up (no malignancy)/local use of immunomodulators (partial malignancy)
conjunctival melanoma(T3d-T4,Lymph node/systemic metastasis):Immunomodulator/Proton therapy/Targeted therapy (with BRAF mutation) /PD-1 therapy (without BRAF mutation)
conjunctival melanoma(T3a-T3c,N0M0):Immunomodulator/Targeted therapy (with BRAF mutation) /PD-1 therapy (without BRAF mutation)
Sponsors
Eye & ENT hospital of Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Different types and stages of conjunctival pigmented lesions;
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating women; 2.Patients who cannot cooperate with diagnosis and treatment: patients with intellectual disability and mental illness; 3.Patients who have received immunotherapy/targeted/radiation-related treatment for conjunctival tumors in the past; 4.Patients with autoimmune diseases; 5.Patients with a history of organ transplantation and currently taking immunosuppressants; 6.People with abnormal cardiopulmonary function and liver and kidney function; 7.People who are known to be allergic to BRAF inhibitors and MEK inhibitors;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tumor range;tumor recurrence;metastasis;patient survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ocular surface inflammation and discomfort;Hematological changes;Intraocular change; | — |
Countries
China
Contacts
Public ContactQian Jiang
Eye & ENT hospital of Fudan University
Outcome results
None listed